{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:48:24Z","timestamp":1740138504764,"version":"3.37.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,2,12]],"date-time":"2022-02-12T00:00:00Z","timestamp":1644624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,12]],"date-time":"2022-02-12T00:00:00Z","timestamp":1644624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s12032-022-01660-9","type":"journal-article","created":{"date-parts":[[2022,2,12]],"date-time":"2022-02-12T08:02:26Z","timestamp":1644652946000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Oncotype DX testing does not affect clinical practice in stage IIa colon cancer"],"prefix":"10.1007","volume":"39","author":[{"given":"Benjamin G.","family":"Allar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangelos","family":"Messaris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vitaliy Y.","family":"Poylin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin L.","family":"Schlechter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7224-4499","authenticated-orcid":false,"given":"Thomas E.","family":"Cataldo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,12]]},"reference":[{"key":"1660_CR1","doi-asserted-by":"crossref","unstructured":"NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990;264(11):1444-50.","DOI":"10.1001\/jama.264.11.1444"},{"issue":"23","key":"1660_CR2","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1056\/NEJMoa032709","volume":"350","author":"T Andr\u00e9","year":"2004","unstructured":"Andr\u00e9 T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343\u201351. https:\/\/doi.org\/10.1056\/NEJMoa032709.","journal-title":"N Engl J Med"},{"issue":"4","key":"1660_CR3","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1200\/jop.2016.017210","volume":"13","author":"J Kannarkatt","year":"2017","unstructured":"Kannarkatt J, Joseph J, Kurniali PC, Al-Janadi A, Hrinczenko B. Adjuvant chemotherapy for stage II colon cancer: a clinical dilemma. J Oncol Pract. 2017;13(4):233\u201341. https:\/\/doi.org\/10.1200\/jop.2016.017210.","journal-title":"J Oncol Pract"},{"issue":"12","key":"1660_CR4","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.1200\/jco.1995.13.12.2936","volume":"13","author":"CG Moertel","year":"1995","unstructured":"Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen CM, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, et al. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II\/Dukes\u2019 B2 colon cancer. J Clin Oncol. 1995;13(12):2936\u201343. https:\/\/doi.org\/10.1200\/jco.1995.13.12.2936.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1660_CR5","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1093\/annonc\/mdi413","volume":"16","author":"JY Douillard","year":"2005","unstructured":"Douillard JY, Bennouna J. Adjuvant chemotherapy for colon cancer: a confusing area! Ann Oncol. 2005;16(12):1853\u20134. https:\/\/doi.org\/10.1093\/annonc\/mdi413.","journal-title":"Ann Oncol"},{"issue":"8","key":"1660_CR6","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1038\/sj.bjc.6604011","volume":"97","author":"W Schippinger","year":"2007","unstructured":"Schippinger W, Samonigg H, Schaberl-Moser R, Greil R, Thodtmann R, Tschmelitsch J, Jagoditsch M, Steger GG, Jakesz R, Herbst F, et al. A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer. Br J Cancer. 2007;97(8):1021\u20137. https:\/\/doi.org\/10.1038\/sj.bjc.6604011.","journal-title":"Br J Cancer"},{"issue":"3","key":"1660_CR7","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3322\/canjclin.57.3.168","volume":"57","author":"BM Wolpin","year":"2007","unstructured":"Wolpin BM, Meyerhardt JA, Mamon HJ, Mayer RJ. Adjuvant treatment of colorectal cancer. CA Cancer J Clin. 2007;57(3):168\u201385.","journal-title":"CA Cancer J Clin"},{"issue":"9604","key":"1660_CR8","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1016\/s0140-6736(07)61866-2","volume":"370","author":"R Gray","year":"2007","unstructured":"Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370(9604):2020\u20139. https:\/\/doi.org\/10.1016\/s0140-6736(07)61866-2.","journal-title":"Lancet"},{"issue":"24","key":"1660_CR9","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.1200\/jco.2016.67.0414","volume":"34","author":"T Yamanaka","year":"2016","unstructured":"Yamanaka T, Oki E, Yamazaki K, Yamaguchi K, Muro K, Uetake H, Sato T, Nishina T, Ikeda M, Kato T, et al. 12-gene recurrence score assay stratifies the recurrence risk in stage II\/III colon cancer with surgery alone: the SUNRISE study. J Clin Oncol. 2016;34(24):2906\u201313. https:\/\/doi.org\/10.1200\/jco.2016.67.0414.","journal-title":"J Clin Oncol"},{"issue":"35","key":"1660_CR10","doi-asserted-by":"publisher","first-page":"4611","DOI":"10.1200\/jco.2010.32.8732","volume":"29","author":"RG Gray","year":"2011","unstructured":"Gray RG, Quirke P, Handley K, Lopatin M, Magill L, Baehner FL, Beaumont C, Clark-Langone KM, Yoshizawa CN, Lee M, et al. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol. 2011;29(35):4611\u20139. https:\/\/doi.org\/10.1200\/jco.2010.32.8732.","journal-title":"J Clin Oncol"},{"issue":"14","key":"1660_CR11","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1200\/jco.2012.45.1096","volume":"31","author":"AP Venook","year":"2013","unstructured":"Venook AP, Niedzwiecki D, Lopatin M, Ye X, Lee M, Friedman PN, Frankel W, Clark-Langone K, Millward C, Shak S, et al. Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581. J Clin Oncol. 2013;31(14):1775\u201381. https:\/\/doi.org\/10.1200\/jco.2012.45.1096.","journal-title":"J Clin Oncol"},{"issue":"36","key":"1660_CR12","doi-asserted-by":"publisher","first-page":"4512","DOI":"10.1200\/jco.2012.47.3116","volume":"31","author":"G Yothers","year":"2013","unstructured":"Yothers G, O\u2019Connell MJ, Lee M, Lopatin M, Clark-Langone KM, Millward C, Paik S, Sharif S, Shak S, Wolmark N. Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU\/LV) and FU\/LV plus oxaliplatin. J Clin Oncol. 2013;31(36):4512\u20139. https:\/\/doi.org\/10.1200\/jco.2012.47.3116.","journal-title":"J Clin Oncol"},{"issue":"25","key":"1660_CR13","doi-asserted-by":"publisher","first-page":"3937","DOI":"10.1200\/jco.2010.28.9538","volume":"28","author":"MJ O'Connell","year":"2010","unstructured":"O\u2019Connell MJ, Lavery I, Yothers G, Paik S, Clark-Langone KM, Lopatin M, Watson D, Baehner FL, Shak S, Baker J, et al. Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II\/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol. 2010;28(25):3937\u201344. https:\/\/doi.org\/10.1200\/jco.2010.28.9538.","journal-title":"J Clin Oncol"},{"key":"1660_CR14","unstructured":"Genomic Health Inc., Application for Economic Hardship. 2019."},{"issue":"1","key":"1660_CR15","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jval.2015.08.013","volume":"19","author":"B Brenner","year":"2016","unstructured":"Brenner B, Geva R, Rothney M, Beny A, Dror Y, Steiner M, Hubert A, Idelevich E, Gluzman A, Purim O, et al. Impact of the 12-gene colon cancer assay on clinical decision making for adjuvant therapy in stage II colon cancer patients. Value Health. 2016;19(1):82\u20137. https:\/\/doi.org\/10.1016\/j.jval.2015.08.013.","journal-title":"Value Health"},{"issue":"2","key":"1660_CR16","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.suronc.2015.02.001","volume":"24","author":"YN You","year":"2015","unstructured":"You YN, Rustin RB, Sullivan JD. Oncotype DX((R)) colon cancer assay for prediction of recurrence risk in patients with stage II and III colon cancer: a review of the evidence. Surg Oncol. 2015;24(2):61\u20136. https:\/\/doi.org\/10.1016\/j.suronc.2015.02.001.","journal-title":"Surg Oncol"},{"issue":"2","key":"1660_CR17","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1185\/03007995.2013.855183","volume":"30","author":"T Cartwright","year":"2014","unstructured":"Cartwright T, Chao C, Lee M, Lopatin M, Bentley T, Broder M, Chang E. Effect of the 12-gene colon cancer assay results on adjuvant treatment recommendations in patients with stage II colon cancer. Curr Med Res Opin. 2014;30(2):321\u20138. https:\/\/doi.org\/10.1185\/03007995.2013.855183.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"1660_CR18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.clcc.2016.07.016","volume":"16","author":"LA Renfro","year":"2017","unstructured":"Renfro LA, Zhang N, Lopatin M, Chao C, Alberts SR. Prospective evaluation of a 12-gene assay on patient treatment decisions and physician confidence in mismatch repair proficient stage IIA colon cancer. Clin Colorectal Cancer. 2017;16(1):23\u201330. https:\/\/doi.org\/10.1016\/j.clcc.2016.07.016.","journal-title":"Clin Colorectal Cancer"},{"issue":"5","key":"1660_CR19","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1634\/theoncologist.2013-0401","volume":"19","author":"G Srivastava","year":"2014","unstructured":"Srivastava G, Renfro LA, Behrens RJ, Lopatin M, Chao C, Soori GS, Dakhil SR, Mowat RB, Kuebler JP, Kim G, et al. Prospective multicenter study of the impact of oncotype DX colon cancer assay results on treatment recommendations in stage II colon cancer patients. Oncologist. 2014;19(5):492\u20137. https:\/\/doi.org\/10.1634\/theoncologist.2013-0401.","journal-title":"Oncologist"},{"issue":"8","key":"1660_CR20","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jval.2012.07.012","volume":"15","author":"J Hornberger","year":"2012","unstructured":"Hornberger J, Lyman GH, Chien R, Meropol NJ. A multigene prognostic assay for selection of adjuvant chemotherapy in patients with T3, stage II colon cancer: impact on quality-adjusted life expectancy and costs. Value Health. 2012;15(8):1014\u201321. https:\/\/doi.org\/10.1016\/j.jval.2012.07.012.","journal-title":"Value Health"},{"issue":"3","key":"1660_CR21","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s11523-017-0494-5","volume":"12","author":"A Puccini","year":"2017","unstructured":"Puccini A, Berger MD, Zhang W, Lenz HJ. What we know about stage II and III colon cancer: it\u2019s still not enough. Target Oncol. 2017;12(3):265\u201375. https:\/\/doi.org\/10.1007\/s11523-017-0494-5.","journal-title":"Target Oncol"},{"key":"1660_CR22","unstructured":"R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, 2018. Available online at https:\/\/www.R-project.org\/."},{"issue":"11","key":"1660_CR23","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1093\/jnci\/djr153","volume":"103","author":"FA Sinicrope","year":"2011","unstructured":"Sinicrope FA, Foster NR, Thibodeau SN, Marsoni S, Monges G, Labianca R, Kim GP, Yothers G, Allegra C, Moore MJ, et al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst. 2011;103(11):863\u201375. https:\/\/doi.org\/10.1093\/jnci\/djr153.","journal-title":"J Natl Cancer Inst"},{"key":"1660_CR24","doi-asserted-by":"publisher","unstructured":"Ueno H, Ishiguro M, Nakatani E, Ishikawa T, Uetake H, Matsuda C, Nakamoto Y, Kotake M, Kurachi K, Egawa T, et al. Prospective multicenter study on the prognostic and predictive impact of tumor budding in stage II colon cancer: results from the SACURA trial. J Clin Oncol. https:\/\/doi.org\/10.1200\/jco.18.02059","DOI":"10.1200\/jco.18.02059"},{"issue":"20","key":"1660_CR25","doi-asserted-by":"publisher","first-page":"3380","DOI":"10.1200\/jco.2009.27.0652","volume":"28","author":"A de la Chapelle","year":"2010","unstructured":"de la Chapelle A, Hampel H. Clinical relevance of microsatellite instability in colorectal cancer. J Clin Oncol. 2010;28(20):3380\u20137. https:\/\/doi.org\/10.1200\/jco.2009.27.0652.","journal-title":"J Clin Oncol"},{"key":"1660_CR26","doi-asserted-by":"publisher","unstructured":"Benson AB, 3rd, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Engstrom PF, et al. NCCN guidelines insights: colon cancer, Version 2.2018. J Natl Compr Canc Netw 2018;16(4):359\u20139. https:\/\/doi.org\/10.6004\/jnccn.2018.0021.","DOI":"10.6004\/jnccn.2018.0021"},{"issue":"16","key":"1660_CR27","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1200\/jco.2014.60.0213","volume":"33","author":"R Dienstmann","year":"2015","unstructured":"Dienstmann R, Salazar R, Tabernero J. Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients. J Clin Oncol. 2015;33(16):1787\u201396. https:\/\/doi.org\/10.1200\/jco.2014.60.0213.","journal-title":"J Clin Oncol"},{"issue":"31","key":"1660_CR28","doi-asserted-by":"publisher","first-page":"5131","DOI":"10.1200\/JCO.2009.22.4949","volume":"27","author":"C Liebig","year":"2009","unstructured":"Liebig C, Ayala G, Wilks J, Verstovsek G, Liu H, Agarwal N, Berger DH, Albo D. Perineural invasion is an independent predictor of outcome in colorectal cancer. J Clin Oncol. 2009;27(31):5131\u20137. https:\/\/doi.org\/10.1200\/JCO.2009.22.4949.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1660_CR29","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/dcr.0000000000001258","volume":"62","author":"M Skancke","year":"2019","unstructured":"Skancke M, Arnott SM, Amdur RL, Siegel RS, Obias VJ, Umapathi BA. Lymphovascular invasion and perineural invasion negatively impact overall survival for stage II adenocarcinoma of the colon. Dis Colon Rectum. 2019;62(2):181\u20138. https:\/\/doi.org\/10.1097\/dcr.0000000000001258.","journal-title":"Dis Colon Rectum"},{"key":"1660_CR30","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0351","author":"I Ben-Aharon","year":"2019","unstructured":"Ben-Aharon I, Goshen-Lago T, Sternschuss M, Morgenstern S, Geva R, Beny A, Dror Y, Steiner M, Hubert A, Idelevich E, et al. Sidedness matters: surrogate biomarkers prognosticate colorectal cancer upon anatomic location. Oncologist. 2019. https:\/\/doi.org\/10.1634\/theoncologist.2018-0351.","journal-title":"Oncologist"},{"key":"1660_CR31","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.4227","author":"F Petrelli","year":"2016","unstructured":"Petrelli F, Tomasello G, Borgonovo K, Ghidini M, Turati L, Dallera P, Passalacqua R, Sgroi G, Barni S. Prognostic survival associated with left-sided vs right-sided colon cancer: a systematic review and meta-analysis. JAMA Oncol. 2016. https:\/\/doi.org\/10.1001\/jamaoncol.2016.4227.","journal-title":"JAMA Oncol"},{"issue":"3","key":"1660_CR32","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1506597","volume":"374","author":"P Dalerba","year":"2016","unstructured":"Dalerba P, Sahoo D, Paik S, Guo X, Yothers G, Song N, Wilcox-Fogel N, Forgo E, Rajendran PS, Miranda SP, et al. CDX2 as a prognostic biomarker in stage II and stage III colon cancer. N Engl J Med. 2016;374(3):211\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1506597.","journal-title":"N Engl J Med"},{"issue":"4","key":"1660_CR33","doi-asserted-by":"publisher","first-page":"e175","DOI":"10.1016\/j.clcc.2016.04.008","volume":"15","author":"O Caritg","year":"2016","unstructured":"Caritg O, Navarro A, Moreno I, Martinez-Rodenas F, Cordeiro A, Munoz C, Ruiz-Martinez M, Santasusagna S, Castellano JJ, Monzo M. Identifying high-risk stage II colon cancer patients: a three-microRNA-based score as a prognostic biomarker. Clin Colorectal Cancer. 2016;15(4):e175\u201382. https:\/\/doi.org\/10.1016\/j.clcc.2016.04.008.","journal-title":"Clin Colorectal Cancer"},{"issue":"5","key":"1660_CR34","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1093\/annonc\/mdx052","volume":"28","author":"R Dienstmann","year":"2017","unstructured":"Dienstmann R, Mason MJ, Sinicrope FA, Phipps AI, Tejpar S, Nesbakken A, Danielsen SA, Sveen A, Buchanan DD, Clendenning M, et al. Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study. Ann Oncol. 2017;28(5):1023\u201331. https:\/\/doi.org\/10.1093\/annonc\/mdx052.","journal-title":"Ann Oncol"},{"key":"1660_CR35","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1186\/1471-2407-14-336","volume":"14","author":"VL Tsikitis","year":"2014","unstructured":"Tsikitis VL, Larson DW, Huebner M, Lohse CM, Thompson PA. Predictors of recurrence free survival for patients with stage II and III colon cancer. BMC Cancer. 2014;14:336. https:\/\/doi.org\/10.1186\/1471-2407-14-336.","journal-title":"BMC Cancer"},{"key":"1660_CR36","doi-asserted-by":"publisher","unstructured":"Lee JH, Ahn J, Park WS, Choe EK, Kim E, Shin R, Heo SC, Jung S, Kim K, Chai YJ, et al. (2019) Colorectal cancer prognosis is not associated with BRAF and KRAS mutations\u2014a STROBE compliant study. J Clin Med https:\/\/doi.org\/10.3390\/jcm8010111.","DOI":"10.3390\/jcm8010111"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-022-01660-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-022-01660-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-022-01660-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T15:31:55Z","timestamp":1648827115000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-022-01660-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,12]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["1660"],"URL":"https:\/\/doi.org\/10.1007\/s12032-022-01660-9","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"type":"print","value":"1357-0560"},{"type":"electronic","value":"1559-131X"}],"subject":[],"published":{"date-parts":[[2022,2,12]]},"assertion":[{"value":"18 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have not disclosed any funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors have not disclosed any competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Obtained, Institutional IRB #2018P000745.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"59"}}